Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 21, 2017JAMA OncologyOpen Access

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

CLChee Khoon LeeThe University of SydneyJMJohnathan ManYahoo (United Kingdom)SLSarah J. LordThe University of Sydney

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lee et al. (2017) studied this question.

synapsesocial.com/papers/69daa62fa6045d71bfa3d78fhttps://doi.org/10.1001/jamaoncol.2017.4427
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis2016 · 1,273 citations
  2. 2Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer2015 · 9,576 citations
  3. 3Genomic landscape of non-small-cell lung cancer in smokers and never-smokers2013 · 31 citations
  4. 4Mutually exclusive expression of CD73 and PDL1 in tumors from patients (pt) with NSCLC, gastroesophageal (GE) and urothelial bladder carcinoma (UBC).2017 · 14 citations
  5. 5Immune marker profiling and PD-L1, PD-L2 expression mechanisms across non-small cell lung cancer mutations.2017 · 5 citations